Loyal, a clinical-stage animal health company focused on developing lifespan extension drugs for dogs, announced the acceptance of its Target Animal Safety (TAS) package by the FDA's Center for Veterinary Medicine. This acceptance is a key step in the approval process for LOY-002, Loyal's primary drug aimed at extending the healthy lifespan of senior dogs. The announcement was made on January 13, 2026, in San Francisco.
Read More
With the Reasonable Expectation of Effectiveness (RXE) and TAS sections of its conditional approval application now accepted, LOY-002 has completed two of the three major technical requirements necessary for market launch. Celine Halioua, Founder and CEO of Loyal, expressed her commitment to achieving FDA approval for a lifespan extension drug, stating that this safety acceptance is a significant milestone toward reaching that goal.
LOY-002, designed as a prescription daily pill, intends to enhance the quality of life for senior dogs by proactively addressing the metabolic factors associated with aging and delaying the onset of related diseases. If approved, LOY-002 will be the first FDA-approved drug for lifespan extension in any species.
The FDA's acceptance of the TAS submission marks a crucial development for Loyal, as it represents the first known safety acceptance for a lifespan extension drug by the FDA. As part of the TAS package, Loyal provided scientific evidence from various studies, including a standard safety study and field safety data from over 400 dogs involved in the pivotal STAY effectiveness trial. The FDA acknowledged that the data supports LOY-002's safety for the intended use.
Dr. Ellen Ratcliff, Loyal's VP of Clinical and Veterinary Medicine, emphasized the importance of safety in preventive care, noting that the FDA's approval of the TAS submission reflects a significant endorsement of Loyal's mission to produce safe and effective longevity drugs for dogs.